Home
About
Overview
Sharing Data
ORCID
Help
History (34)
Efficacy and safety of brolucizumab versus aflibercept in eyes with early persistent retinal fluid: 96-week outcomes from the HAWK and HARRIER studies.
A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors.
Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.
Preventability of Early Versus Late Hospital Readmissions in a National Cohort of General Medicine Patients.
Inflammasome activation in neurodegenerative diseases.
See All 34 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Inflammasome activation in neurodegenerative diseases.
Ravichandran KA, Heneka MT. Inflammasome activation in neurodegenerative diseases. Essays Biochem. 2021 12 22; 65(7):885-904.
View in:
PubMed
subject areas
Amyloid beta-Peptides
Animals
Humans
Inflammasomes
Mice
Microglia
Neurodegenerative Diseases
NLR Family, Pyrin Domain-Containing 3 Protein
authors with profiles
Michael Thomas Heneka MD